Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review

Eva Z. Reininghaus, Mirko Manchia, Nina Dalkner*, Nina Bonkat, Alessio Squassina, Isabel Hodl, Eduard Vieta, Andreas Reif, Tomas Hajek, Mikael Landén, Christoph U. Correll, Jan Scott, Bruno Etain, Marcella Rietschel, Veerle Bergink, Monica Martinez-Cengotitabengoa, Lars Vedel Kessing, Andrea Fagiolini, Michael Bauer, Guy GoodwinAna Gonzalez-Pinto, Ralph W. Kupka, Thomas G. Schulze, Trine V. Lagerberg, Ayşegül Yildiz, Chantal Henry, Gunnar Morken, Phillip Ritter, René Ernst Nieslen, Rasmus W. Licht, Andreas Bechdolf, Ole A. Andreassen, Frederike Tabea Fellendorf

*Kontaktforfatter

Publikation: Bidrag til tidsskriftReview (oversigtsartikel)peer review

4 Citationer (Scopus)
23 Downloads (Pure)

Abstract

Bipolar disorder (BD) might be associated with higher infection rates of coronavirus disease (COVID-19) which in turn could result in worsening the clinical course and outcome. This may be due to a high prevalence of somatic comorbidities and an increased risk of delays in and poorer treatment of somatic disease in patients with severe mental illness in general. Vaccination is the most important public health intervention to tackle the ongoing pandemic. We undertook a systematic review regarding the data on vaccinations in individuals with BD. Proportion of prevalence rates, efficacy and specific side effects of vaccinations and in individuals with BD were searched. Results show that only five studies have investigated vaccinations in individuals with BD, which substantially limits the interpretation of overall findings. Studies on antibody production after vaccinations in BD are very limited and results are inconsistent. Also, the evidence-based science on side effects of vaccinations in individuals with BD so far is poor.

OriginalsprogEngelsk
TidsskriftEuropean Neuropsychopharmacology
Vol/bind54
Sider (fra-til)90-99
Antal sider10
ISSN0924-977X
DOI
StatusUdgivet - jan. 2022

Bibliografisk note

Funding Information:
AF is /has been a consultant and/or a speaker and/or has received research grants from Angelini, Apsen, Boheringer Ingelheim, Daiichi Sankyo, Doc Generici, Glaxo Smith Kline, Italfarmaco, Lundbeck, Janssen, Mylan, Neuraxpharm, Otsuka, Pfizer, Recordati, Sanofi Aventis, Sunovion, Vifor.

Funding Information:
MB has received institutional grants from Deutsche Forschungsgemeinschaft (DFG), Bundesministerium für Bildung und Forschung (BMBF), and European Commission. He served in advisory boards for GH Research, Janssen-Cilag, neuraxpharm, Novartis, Sandoz, Shire International, Sumitomo Dainippon, Sunovion, and Takeda, and received speaker honoraria for Aristo, Hexal, Janssen Pharmaceutica NV, Janssen-Cilag, and Sunovion, outside the submitted work.

Funding Information:
CC has been a consultant and/or advisor to or has received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma.

Publisher Copyright:
© 2021 The Author(s)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review'. Sammen danner de et unikt fingeraftryk.

Citationsformater